In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celyad SA

www.celyad.com

Latest From Celyad SA

All To Play For: CAR-T Specialist Celyad’s Big Year

Celyad’s leadership team talks to Scrip about the critical nature of the coming months for its lead cancer therapy product, and CAR-T market differentiation.

BioPharmaceutical Commercial

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

Clinical Trials Cancer

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.

Clinical Trials Cancer

Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US

Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Cardio3 BioSciences SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Celyad SA
  • Senior Management
  • Filippo Petti, CEO
    David Gilham , PhD, VP, R&D
    Jean-Pierre Latere, PhD, COO
  • Contact Info
  • Celyad SA
    Phone: (32) 10 39 41 00
    2 Rue Edouard Belin
    Axis Bus. Park
    Mont-Saint-Guibert, B-1435
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register